title: TX14(A), a prosaposin-derived peptide, reverses established nerve disorders in streptozotocin-diabetic rats and prevents them in galactose-fed rats.
abstract: Recently, TX14(A), a prosaposin-derived neurotrophic peptide, was shown to prevent both large and small fiber deficits in streptozotocin diabetes. Here, the efficacy of TX14(A) in reversing established nerve conduction disorders in streptozotocin diabetes, a model of insulin deficiency, and preventing them in galactose feeding, an insulin-replete model of polyol pathway flux, was investigated. Following streptozotocin injection (50 mg/kg ip), TX14(A) treatment (1 mg/kg ip thrice weekly) was initiated in half of the animals. After 8 wk, treatment was begun in half of the untreated animals and discontinued in half of the treated animals, and the experiment continued for 6 wk. TX14(A) reversed established motor and sensory nerve conduction deficits in streptozotocin-diabetic rats and the impact of previous treatment was still evident 3 wk after withdrawal. With the onset of 40% galactose feeding, the same dose of TX14(A) was given to half of the control and half of the galactose-fed animals for 16 wk. TX14(A) was without effect in control animals but it attenuated motor and sensory nerve conduction deficits in galactose-fed rats, an effect associated with amelioration of axonal dwindling in the sciatic nerve. These observations extend the therapeutic utility of TX14(A) and highlight its potential in treating established diabetic neuropathy.
authors.affiliation: Department of Pathology, School of Medicine, University of California, San Diego, La Jolla, 92093-0612, USA.
authors.forename: A P
authors.initials: AP
authors.lastname: Mizisin
authors.forename: R C
authors.initials: RC
authors.lastname: Steinhardt
authors.forename: J S
authors.initials: JS
authors.lastname: O'Brien
authors.forename: N A
authors.initials: NA
authors.lastname: Calcutt
mesh_terms: D000818:Animals; D001369:Axons / Q000187:drug effects / Q000473:pathology; D001786:Blood Glucose / Q000502:physiology; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy*; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000517:prevention & control*; D004032:Diet; D005260:Female; D005690:Galactose / Q000008:administration & dosage*; D006023:Glycoproteins / Q000494:pharmacology / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D009046:Motor Neurons / Q000187:drug effects / Q000473:pathology; D009414:Nerve Growth Factors / Q000494:pharmacology* / Q000627:therapeutic use; D009431:Neural Conduction / Q000187:drug effects; D009475:Neurons, Afferent / Q000187:drug effects / Q000473:pathology; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D049231:Saposins; D013311:Streptozocin / Q000008:administration & dosage
chemical_list: D001786:Blood Glucose; D006023:Glycoproteins; D009414:Nerve Growth Factors; D010455:Peptides; C483347:Psap protein, rat; D049231:Saposins; C101246:prosaptide; D013311:Streptozocin; D005690:Galactose